<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560690</url>
  </required_header>
  <id_info>
    <org_study_id>83/53</org_study_id>
    <nct_id>NCT00560690</nct_id>
  </id_info>
  <brief_title>The Effect of Adding Metformin to the Treatment of Hepatitis C</brief_title>
  <official_title>Effect and Safety of Adding Metformin to the Standard Treatment of Hepatitis C on Sustained Viral Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance is known to adversely effect viral response to treatment in hepatitis C
      patients

      We are aiming to study the effect of an insulin sensitizer, metformin, in viral response of
      hepatitis C to treatment with pegylated interferon and ribavirin in a double blind randomized
      controlled trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with hepatitis C will be randomized to receive standard treatment with or without
      metformin. The results will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained viral response, defined as undetectable virus RNA 6 months after end of treatment</measure>
    <time_frame>6 months after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse effects leading to discontinuation of treatment</measure>
    <time_frame>anytime during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid viral response, defined as undetectable viral RNA one month after start of treatment</measure>
    <time_frame>one month after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early viral response, defined as undetectable viral RNA or 2 log drop in viral count three month after start of treatment</measure>
    <time_frame>three months after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard treatment with pegylated interferon and ribavirin + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard treatment with pegylated interferon and ribavirin + metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg oral three times a day for 6 months</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon</intervention_name>
    <description>180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic hepatitis C

          -  Iranian nationality

          -  Treatment naive

        Exclusion Criteria:

          -  cirrhosis

          -  diabetes mellitus

          -  HBV/HIV coinfection

          -  contraindications of metformin, interferon, ribavirin

          -  severe medical conditions (e.g. CHF, CRF, psychosis, ...)

          -  not consenting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahin Merat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Digestive Disease Research Center, Medical Sciences / University of Tehran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reza Malekzadeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Digestive Disease Research Center, Medical Sciences / University of Tehran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shariati Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shahin Merat</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>metformin</keyword>
  <keyword>Insulin Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

